4
Crizotinib: unmet need in
ALK
+ NSCLC
10
20
30
5
15
25
7.0
10.9
HR=0.45
(95% CI 0.35–0.60)
Log-rank p<0.0001
Crizotinib (n=172)
Chemo (n=171)
PFS probability
0.8
0.6
0.4
0.2
0
1.0
Time (months)
0
35
PROFILE 1014: approximately half of patients progress
within one year of beginning front-line crizotinib therapy
2
•
1. Camidge, et al. Lancet Oncol 2012; 2. Solomon, et al. NEJM 2014; 3. Costa, et al. J Clin Oncol 2015
PROFILE 1001: resistance
1
Change from baseline (%)
50
0
–50
–100
100
Best overall response (RECIST v1.0)
Progressive disease
Stable disease
Partial response
Complete response
CNS progression
3
10
20
5
15
No BL BM
Previously treated BL BM
Previously untreated BL BM
PFS probability
0.8
0.6
0.4
0.2
0
1.0
Time (months)
0
25
Approximately half of
patients treated with
crizotinib progress in
the CNS
